Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced its participation in two upcoming investor conferences. They will attend the Craig-Hallum Virtual Institutional Investor Conference on June 2, focusing on one-on-one meetings. Additionally, they will present at the Jefferies Virtual Healthcare Conference on June 4, from 2:00 to 2:25 PM EST, where one-on-one meetings will also be available. The company is committed to developing products to enhance survival and quality of life for patients with unmet medical needs.

HANOVER, MD, May 26, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that management will participate in two upcoming investor conferences:

• Craig-Hallum Virtual Institutional Investor Conference
  • June 2: (1x1 meetings only)
• Jefferies Virtual Healthcare Conference
  • June 4: 2:00 to 2:25PM EST (Presentation and 1x1 meetings)
  • https://wsw.com/webcast/jeff174/pcsa/1841697
    

To schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com.

About Processa Pharmaceuticals, Inc.

The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com .

Forward-Looking Statements

This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the registration statement relating to the securities being sold in this offering, which identifies important risk factors which could cause actual results to differ from those contained in the forward-looking statements.

For More Information:
Michael Floyd
mfloyd@processapharma.com
301-651-4256

James Carbonara
Hayden IR
(646) 755-7412
james@haydenir.com 

FAQ

What investor conferences is Processa Pharmaceuticals attending in June 2021?

Processa Pharmaceuticals will attend the Craig-Hallum Virtual Institutional Investor Conference on June 2 and the Jefferies Virtual Healthcare Conference on June 4.

What is the schedule for the Jefferies Virtual Healthcare Conference for Processa Pharmaceuticals?

The Jefferies Virtual Healthcare Conference presentation for Processa Pharmaceuticals is scheduled for June 4 from 2:00 to 2:25 PM EST.

How can I schedule a meeting with Processa Pharmaceuticals management during the investor conferences?

Interested parties can schedule one-on-one meetings with Processa Pharmaceuticals management through their conference representative or by contacting James at Hayden IR.

What are the main goals of Processa Pharmaceuticals?

Processa Pharmaceuticals aims to develop products that improve survival and quality of life for patients with unmet medical needs.

What are the clinical pipeline programs of Processa Pharmaceuticals?

Processa Pharmaceuticals' active clinical pipeline programs include PCS6422 for metastatic colorectal and breast cancer, PCS499 for ulcerative necrobiosis lipoidica, and PCS12852 for GI motility disorders.